![]() |
市場調查報告書
商品編碼
1495568
軟霧吸入器市場 - 按產品類型(一次性、可重複使用)、年齡層(成人、兒童)、應用(氣喘、慢性阻塞性肺病)、配銷通路(醫院藥房、零售藥房、線上藥房)、最終用途與全球預測, 2024 - 2032Soft Mist Inhalers Market - By Product Type (Disposable, Reusable), Age-Group (Adult, Pediatric), Application (Asthma, COPD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-Use & Global Forecast, 2024 - 2032 |
由於氣喘、慢性阻塞性肺病 (COPD) 和過敏性鼻炎等呼吸系統疾病盛行率不斷上升,2024 年至 2032 年間,軟霧吸入器市場規模將以 9.2% 的複合年成長率成長。根據世界衛生組織的數據,慢性阻塞性肺病 (COPD) 是一種常見的肺部疾病,它會導致呼吸困難,每年奪走超過 300 萬人的生命。與傳統的定量吸入器(MDI) 和乾粉吸入器(DPI) 相比,軟霧化器具有使用方便、連續給藥以及降低手肺協調問題風險等優勢,使其越來越受到患者的歡迎,尤其是老年人和老年人。
最近,製藥公司擴大投資於研發活動,透過最佳化藥物配方、設備設計和推進劑系統來提高軟霧化器的有效性、安全性和效率。這些創新旨在透過促進醫療保健專業人員和患者採用軟霧化器來提高患者的依從性,最大限度地減少副作用並最大限度地提高治療效果。
整個產業分為產品類型、年齡層、應用、配銷通路、最終用途和地區。
根據產品類型,一次性細分市場的軟霧吸入器市場在2024 年至2032 年間將達到8.7% 的成長率。需求。這些吸入器還可以降低醫療機構中交叉污染和感染傳播的風險,解決與病人安全和感染控制相關的問題。
預計從 2024 年到 2032 年,氣喘應用的軟霧吸入器市場複合年成長率將達到 9.4%。 全球氣喘盛行率的不斷上升導致對有效、方便的吸入療法的需求更高。與定量吸入器 (MDI) 和乾粉吸入器 (DPI) 等傳統吸入裝置相比,軟霧吸入器具有多種優勢,包括改善肺部沉積、減少手肺協調問題以及易於使用。這些特性使它們特別適合氣喘患者,包括兒童和老年人。
由於城市化、污染和生活方式的改變,亞太地區軟霧吸入器產業預計在 2024 年至 2032 年期間將以 9.9% 的複合年成長率快速成長。中國和印度等新興經濟體的醫療保健支出不斷增加,醫療服務的可近性不斷提高。醫療保健基礎設施的快速進步,加上人們對呼吸系統健康和治療選擇的認知不斷提高,將進一步推動區域市場的成長。
Soft mist inhalers market size will grow at 9.2% CAGR between 2024 and 2032, driven by the increasing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. As per WHO, chronic obstructive pulmonary disease (COPD), a frequent lung ailment, led to breathing difficulties while claiming the lives of over 3 million people annually. Soft nebulizers provide advantages over traditional metered dose inhalers (MDIs) and dry powder inhalers (DPIs), including ease of use, continuous drug delivery, and reduced risk of hand-lung coordination problems, making them increasingly popular with patients, especially the old and children.
Lately, pharmaceutical companies are increasingly investing in R&D activities to improve the effectiveness, safety, and efficiency of soft nebulizers by optimizing drug formulations, device design and propellant systems. These innovations aim to improve patient compliance, minimize side effects and maximize treatment outcomes by promoting the adoption of soft nebulizers among healthcare professionals and patients.
The overall industry is classified into product type, age group, application, distribution channel, end-use, and region.
Based on product type, the soft mist inhalers market from the disposable segment will witness 8.7% growth rate between 2024 and 2032.Disposable inhalers provide convenience and portability while reducing the need for cleaning and maintenance of reusable devices. These inhalers also reduce the risk of cross-contamination and infection transmission in healthcare settings, addressing concerns related to patient safety and infection control.
Soft mist inhalers market from the asthma application is anticipated to witness 9.4% CAGR from 2024 to 2032. The increasing prevalence of asthma worldwide has led to the higher demand for effective and convenient inhalation therapies. Soft mist inhalers provide advantages over traditional inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), including improved lung deposition, reduced hand-lung coordination issues, and ease of use. These properties are making them particularly suitable for asthma patients, including children and the elderly.
Asia Pacific soft mist inhalers industry is anticipated to grow at a significant pace at 9.9% CAGR over 2024-2032, attributed to urbanization, pollution, and changing lifestyles. There is rising healthcare expenditure and improving access to medical services in emerging economies like China and India. Rapid advancements in healthcare infrastructure, coupled with growing awareness about respiratory health and treatment options will further fuel the regional market growth.